Industry Information

Urofollitropin is administered via injection into the muscle or under the skin.

  Urofollitropin is used for the treatment of infertility in women by stimulating egg production in the ovaries. It is a follicle-stimulating hormone (FSH) that is produced in a laboratory setting using recombinant DNA technology.

  Urofollitropin is administered via injection into the muscle or under the skin. The dosage and duration of treatment will vary depending on the patient's medical history, the cause of infertility and their response to the medication.

  Before starting treatment with urofollitropin, patients should undergo a thorough medical evaluation, including a physical exam, blood tests, and a transvaginal ultrasound. This will help determine the underlying cause of infertility and the appropriate treatment course.

Urofollitropin is administered via injection into the muscle or under the skin.

  It is important to note that urofollitropin should only be used under the supervision of a licensed healthcare professional. Patients should follow all instructions given by their doctor, including the timing and dosage of injections, as well as any potential side effects or complications.

  Possible side effects of urofollitropin include headache, nausea, vomiting, abdominal pain, bloating, and ovarian hyperstimulation syndrome. Women who experience severe or persistent side effects should contact their doctor immediately.

  In conclusion, urofollitropin is an effective treatment for infertility in women, but it should only be used under the guidance of a healthcare professional. Patients should follow all instructions and closely monitor for any potential side effects.